CVS HEALTH Q3 2026 earnings

CVS · 2026-11-04 06:31 BMO ET · 8-K on SEC · 10-Q on SEC

Total revenues increased 5.4% driven by growth in Health Services and Health Care Benefits segments, while adjusted operating income increased 21.2% across all segments.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$108.4B+5.4%—Exhibit 99.1
EPS (GAAP)$1.68+5.81—Exhibit 99.1
EPS (adjusted)$2.09+0.49—Exhibit 99.1
Net income$2.17B+$6.16B—Consolidated third quarter results

Revenue breakdown

SegmentActualYoYShare of revenueNote
Health Care Benefits$36.86B+2.4%34%Adjusted operating income increased 190.4% driven by improved Government business performance
Health Services$53.96B+9.5%50%Adjusted operating income increased 2.7% driven by improved purchasing economics and pharmacy drug mix
Pharmacy & Consumer Wellness$35.50B-2.0%33%Adjusted operating income increased 10.6% driven by core pharmacy strength and Rite Aid acquisitions

Margins and costs

  • Gross margin 19.2% (prior 18.1%, change +1.1 pp)
  • Operating expenses $11.33B (+0.4% YoY)
  • One-offs in the quarter Goodwill impairment $5.73B; Omnicare guarantee $193M; Gain on deconsolidation of subsidiary $483M; Acquisition-related integration costs $35M
  • Effective tax rate 24% (prior-year 15%, year-to-date 23%)
  • Non-GAAP bridge Excludes amortization of intangible assets, net realized capital gains/losses, acquisition-related integration costs, Omnicare guarantee, goodwill impairment, clinic closure charges, opioid litigation charges, legacy litigation charges, losses on Accountable Care assets, office real estate optimization charges, and gain on deconsolidation of subsidiary.

KPIs

MetricActualPrior quarterPrior yearChange
MBR91.3%87.4%92.8%+3.9 pp
Medical membership26.1M26.0M26.7M+0.1M
Days claims payable41.9 days41.7 days41.9 days+0.2 days
Pharmacy claims processed481.7M473M475.6M+6.1M
Prescriptions filled470M457M461.4M+8.6M
Same store sales-0.6%2.6%15.4%-3.2 pp

Guidance

MetricGuidePrior guideChange
RevenueAt least $422.3BAt least $414.0B+$8.3B
Adjusted EPS$7.90-$8.10$7.90-$8.10No change
Cash flow from operationsAt least $10.0BAt least $10.0BNo change

What drove it

  • Revenue story Health Services (+9.5%) and Health Care Benefits (+2.4%) drove growth, while Pharmacy & Consumer Wellness decreased 2.0% due to regulatory price reductions and generic introductions.
  • EPS story EPS increased due to improved adjusted operating income across all segments and the absence of a $5.73 billion goodwill impairment charge in the prior year.
  • One-off check Goodwill impairment $5.73B (non-recurring), Omnicare guarantee $193M (non-recurring), Gain on deconsolidation of subsidiary $483M (non-recurring).

The good

  • Adjusted operating income increased 21.2% across all segments
  • MBR improved to 91.3% from 92.8% YoY
  • Aetna Medicare Advantage 69% of members in 4+ star plans (2nd among large MA organizations)

The bad

  • Pharmacy & Consumer Wellness revenue decreased 2.0% YoY
  • Same store sales decreased 0.6% YoY
  • Commercial premiums decreased 16.9% YoY

The ugly

  • none

Open questions

  • What specific actions will CVS take to reverse the decline in Commercial premiums?
  • How will the Omnicare guarantee liability impact future operating income?
  • What is the timeline for the sale of Omnicare assets and the resolution of the guarantee liability?
Full release

CVS HEALTH (CVS) earnings release, November 4, 2026

CVS HEALTH Corp (CVS) · Form 8-K, Item 2.02 · Filed · SEC filing

Third quarter GAAP diluted earnings per share of $1.68 increased from a loss per share of $3.13 in the prior year, reflecting the absence of a $5.7 billion goodwill impairment charge recorded in the third quarter of 2025. Adjusted EPS of $2.09 increased from $1.60 in the prior year, primarily due to improved adjusted operating income in the Health Care Benefits segment, reflecting continued execution of its margin recovery plan.

The Company is increasing its full-year 2026 GAAP diluted EPS, Adjusted EPS and cash flow from operations guidance to reflect increases in the Health Care Benefits and Pharmacy & Consumer Wellness segments, while maintaining a cautious view for the remainder of the year in light of continued elevated cost trends and the potential for macro headwinds.¹

Consolidated third quarter results

For the three months ended September 30, 2026 compared to the prior year:

• Total revenues increased 5.4% primarily driven by growth in the Health Services and Health Care Benefits segments.

• During the three months ended September 30, 2026, the Company generated operating income of $3.6 billion compared to an operating loss of $3.2 billion in the prior year. The difference was primarily driven by the absence of the $5.7 billion goodwill impairment charge related to the Health Care Delivery reporting unit recorded in the prior year and the increase in adjusted operating income described below.

• Adjusted operating income increased 21.2% primarily driven by increases across all operating segments. See pages³ through⁵ for additional discussion of the adjusted operating income performance of the Company’s segments.

Operational Updates

• More than 69 percent of Aetna®

Medicare Advantage members are in 2027 plans rated 4 stars or higher (out of 5 stars) by the Centers for Medicare & Medicaid Services. These results position Aetna second among large, publicly traded Medicare Advantage organizations in the Star Ratings program. For the third consecutive year, Aetna’s commitment to care has driven strong performance across various clinical quality, preventive care and member experience measures.

• CVS Health continues to lead the industry through enhancements to its direct-to-consumer weight management offerings to improve access, affordability, care and support for GLP-1 medications. CVS Pharmacy offers all FDA-approved GLP-1s. Through its integrated offerings, CVS Health can combine a MinuteClinic digital weight loss visit with a licensed clinician, same-day medication pickup at 9,000 local CVS Pharmacy locations, and in-person pharmacist support in one connected experience, with no membership or recurring monthly fee.

• Health100™, a CVS Health subsidiary, earned the CARIN Code of Conduct for Consumer-Facing Applications Accreditation from DirectTrust® for the Health100 mobile app. Health100 provides consumers with cost transparency and the ability to reduce out-of-pocket costs, helps them find and access expanded care, and offers integrated, simpler health care navigation and chronic condition management, including real-time proactive support to stay on track.²

Health Care Benefits segment

The Health Care Benefits segment offers a full range of insured and self-insured (“ASC”) medical, pharmacy, dental and behavioral health products and services. The segment results for the three and nine months ended September 30, 2026 and 2025 were as follows:

• Total revenues increased 2.4% for the three months ended September 30, 2026 compared to the prior year primarily driven by an increase in the Government business, partially offset by a decline as a result of the Company’s exit of the individual exchange business in 2026.

• Adjusted operating income increased significantly in the three months ended September 30, 2026 compared to the prior year primarily driven by improved underlying performance in the Government business.

• The MBR decreased to 91.3% in the three months ended September 30, 2026 compared to 92.8% in the prior year primarily driven by improved underlying performance in the Government business.

• Medical membership as of September 30, 2026 of 26.1 million remained consistent compared with June 30, 2026.

• Prior years’ health care costs payable estimates developed favorably by $1.3 billion during the nine months ended September 30, 2026.

• Days claims payable were 41.9 days as of September 30, 2026, an increase of 0.2 days compared to June 30, 2026.³

Health Services segment

The Health Services segment provides a full range of pharmacy benefit management solutions, delivers health care services in its medical clinics, virtually, and in the home, and offers provider enablement solutions. The segment results for the three and nine months ended September 30, 2026 and 2025 were as follows:

• Total revenues increased 9.5% for the three months ended September 30, 2026 compared to the prior year primarily driven by pharmacy drug mix and brand inflation, partially offset by continued pharmacy client price improvements.

• Adjusted operating income increased 2.7% for the three months ended September 30, 2026 compared to the prior year primarily driven by improved purchasing economics and pharmacy drug mix, partially offset by continued pharmacy client price improvements.

• Pharmacy claims processed increased 1.3% on a 30-day equivalent basis for the three months ended September 30, 2026 compared to the prior year.⁴

Pharmacy & Consumer Wellness segment... (truncated)ne months ended September 30, 2026 and 2025 were as follows:

• Total revenues decreased 2.0% for the three months ended September 30, 2026 compared to the prior year primarily driven by regulatory-related price reductions on certain drugs, the impact of recent generic drug introductions and pharmacy reimbursement pressure. These decreases were partially offset by pharmacy drug mix, increased prescription volume, including contributions from the Company’s Rite Aid asset acquisitions which were completed during the third quarter of 2025, and brand inflation.

• Adjusted operating income increased 10.6% for the three months ended September 30, 2026 compared to the prior year primarily driven by core pharmacy strength and contributions from the Company’s Rite Aid asset acquisitions. These increases were partially offset by continued business investments and the impact of consumer dynamics.

• Prescriptions filled increased 1.9% on a 30-day equivalent basis for the three months ended September 30, 2026 compared to the prior year primarily driven by increased utilization and incremental volume resulting from the Company’s Rite Aid prescription file acquisitions, partially offset by the absence of long-term care pharmacy prescription volume following the deconsolidation of Omnicare, LLC (“Omnicare”) in September 2025.⁵

About CVS Health

CVS Health is a leading health solutions company simplifying health care one person, one family and one community at a time. As of September 30, 2026, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 87 million plan members. The Company also serves an estimated 37 million people through a broad range of health insurance products and related services. The Company’s integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.

Teleconference and Webcast

The Company will be holding a conference call today for investors at 8:00 a.m. (Eastern Time) to discuss its third quarter results. An audio webcast of the call will be broadcast simultaneously for all interested parties through the Investor Relations section of the CVS Health website at http://investors.cvshealth.com. This webcast will be archived and available on the website for a one-year period following the conference call.

Non-GAAP Financial Information

The Company presents both GAAP and non-GAAP financial measures in this press release to assist in the comparison of the Company’s past financial performance with its current financial performance. See “Non-GAAP Financial Information” beginning on page¹⁰ and endnotes beginning on page²⁰ for explanations of non-GAAP financial measures presented in this press release. See pages¹² through¹⁴ and page¹⁹ for reconciliations of each non-GAAP financial measure used in this release to the most directly comparable GAAP financial measure.

Financial statements

Income Statement

Three Months Ended September 30, — Exhibit 99.1 (in billions)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025
Total revenues108.4102.9
Diluted earnings (loss) per share1.68-3.13
Adjusted EPS (2)2.091.6

Income Statement

Three Months Ended September 30, — Consolidated third quarter results (in millions)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Three Months Ended September 30, – ChangeNine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025Nine Months Ended September 30, – Change
Total revenues108,399102,8715,528314,921296,37418,547
Operating income (loss)3,566-3,2076,77312,9492,54810,401
Adjusted operating income (1)4,1943,45973514,50111,8462,655
Net income (loss)2,171-3,9906,1618,123-1,1959,318
Diluted earnings (loss) per share1.68-3.134.816.29-0.937.22
Adjusted EPS (2)2.091.60.497.245.661.58

Income Statement

Three Months Ended September 30, (in millions)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Three Months Ended September 30, – 2025Three Months Ended September 30, – ChangeNine Months Ended September 30, – 2026Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025Nine Months Ended September 30, – 2025Nine Months Ended September 30, – ChangeNine Months Ended September 30, – Change
Total revenues36,85535,993862110,364107,0613,303
Adjusted operating income (1)9123145986,3793,6152,764
Medical benefit ratio (“MBR”) (3)91.3%92.8%-1.587.8%90%-2.2%
Medical membership (4)26.126.7-0.6

Income Statement

Three Months Ended September 30, (in millions)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Three Months Ended September 30, – ChangeNine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025Nine Months Ended September 30, – Change
Total revenues53,96449,2664,698153,996139,18114,815
Adjusted operating income (1)2,1062,050565,3285,228100
Pharmacy claims processed (5) (6)481.7475.66.11,419.41,408.810.6

Income Statement

Three Months Ended September 30, (in millions)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Three Months Ended September 30, – ChangeNine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025Nine Months Ended September 30, – Change
Total revenues35,49836,214-716101,303101,707-404
Adjusted operating income (1)1,6351,4781574,3074,129178
Prescriptions filled (5) (6)470461.48.61,378.21,33543.2

Income Statement

Three Months Ended September 30, — (Unaudited) (in millions)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Products69,22564,590197,670182,866
Premiums34,56633,719103,474100,734
Services3,9613,93011,91511,135
Net investment income6476321,8621,639
Total revenues108,399102,871314,921296,374
Operating costs:
Cost of products sold61,18557,045175,491162,107
Health care costs32,31632,02093,15992,472
Operating expenses11,33211,28833,32233,522
Goodwill impairment5,7255,725
Total operating costs104,833106,078301,972293,826
Operating income (loss)3,566-3,20712,9492,548
Gain on deconsolidation of subsidiary483483
Interest expense-747-784-2,278-2,332
Other income30269383
Income (loss) before income tax provision2,849-3,48210,764782
Income tax provision6785082,6411,977
Net income (loss)2,171-3,9908,123-1,195
Net (income) loss attributable to noncontrolling interests115-2920
Net income (loss) attributable to CVS Health2,172-3,9758,094-1,175
Net income (loss) per share attributable to CVS Health:
Basic1.7-3.136.33-0.93
Diluted1.68-3.136.29-0.93
Weighted average shares outstanding:
Basic1,2821,2691,2781,266
Diluted1,2911,2691,2861,266

Income Statement

Three Months Ended September 30, 2026 (in millions)

Three Months Ended September 30, 2026 – Health Care BenefitsThree Months Ended September 30, 2026 – Health ServicesThree Months Ended September 30, 2026 – Pharmacy & Consumer WellnessThree Months Ended September 30, 2026 – Corporate/ OtherThree Months Ended September 30, 2026 – Consolidated Totals
Operating income (loss) (GAAP measure)6531,9801,573-6403,566
Amortization of intangible assets236126621425
Net realized capital (gains) losses23-26-3
Acquisition-related integration costs1313
Omnicare guarantee193193
Adjusted operating income (loss) (1)9122,1061,635-4594,194

Income Statement

Nine Months Ended September 30, 2026 (in millions)

Nine Months Ended September 30, 2026 – Health Care BenefitsNine Months Ended September 30, 2026 – Health ServicesNine Months Ended September 30, 2026 – Pharmacy & Consumer WellnessNine Months Ended September 30, 2026 – Corporate/ OtherNine Months Ended September 30, 2026 – Consolidated Totals
Operating income (loss) (GAAP measure)5,6504,9304,118-1,74912,949
Amortization of intangible assets70939818921,298
Net realized capital losses20626
Acquisition-related integration costs3535
Omnicare guarantee193193
Adjusted operating income (loss) (1)6,3795,3284,307-1,51314,501

Income Statement

Nine Months Ended September 30, 2025 (in millions)

Nine Months Ended September 30, 2025 – Health Care BenefitsNine Months Ended September 30, 2025 – Health ServicesNine Months Ended September 30, 2025 – Pharmacy & Consumer WellnessNine Months Ended September 30, 2025 – Corporate/ OtherNine Months Ended September 30, 2025 – Consolidated Totals
Operating income (loss) (GAAP measure)2,729-1,5703,014-1,6252,548
Amortization of intangible assets88142618421,493
Net realized capital (gains) losses1-157359
Acquisition-related integration costs100100
Goodwill impairment5,7255,725
Health Care Delivery clinic closure charge8383
Opioid litigation charge320320
Legacy litigation charges2919291,220
Loss on Accountable Care assets288288
Office real estate optimization charges42410
Adjusted operating income (loss) (1)3,6155,2284,129-1,12611,846

Income Statement

The following are reconciliations of financial measures of the Company’s segments to the consolidated totals: (in millions)

Health Care BenefitsHealth ServicesPharmacy & Consumer WellnessCorporate/ OtherIntersegment Eliminations (a)Consolidated Totals
September 30, 2026
Total revenues36,85553,96435,498205-18,123108,399
Adjusted operating income (loss) (1)9122,1061,635-4594,194
September 30, 2025
Total revenues35,99349,26636,214133-18,735102,871
Adjusted operating income (loss) (1)3142,0501,478-3833,459
September 30, 2026
Total revenues110,364153,996101,303478-51,220314,921
Adjusted operating income (loss) (1)6,3795,3284,307-1,51314,501
September 30, 2025
Total revenues107,061139,181101,707362-51,937296,374
Adjusted operating income (loss) (1)3,6155,2284,129-1,12611,846

Income Statement

The following table summarizes the Health Care Benefits segment’s performance for the respective periods: (in millions)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025Nine Months Ended September 30, – 2025Change – Three Months Ended September 30, 2026 vs 2025 – $Change – Three Months Ended September 30, 2026 vs 2025 – %Change – Nine Months Ended September 30, 2026 vs 2025 – $$Change – Nine Months Ended September 30, 2026 vs 2025 – %
Premiums34,56933,739103,480100,7318302.5%2,7492.7%
Services1,8311,7415,4595,023905.2%4368.7%
Net investment income4555131,4251,307-58-11.3%1189.0%
Total revenues36,85535,993110,364107,0618622.4%3,3033.1%
Health care costs31,55631,31990,82790,6962370.8%1310.1%
MBR (Health care costs as a % of premium revenues) (3)91.3%92.8%87.8%90%-150-220
Operating expenses4,6464,62113,88713,636250.5%2511.8%
Operating expenses as a % of total revenues12.6%12.8%12.6%12.7%
Operating income653535,6502,7296001132.1%2,921107.0%
Operating income as a % of total revenues1.8%0.1%5.1%2.5%
Adjusted operating income (1)9123146,3793,615598190.4%2,76476.5%
Adjusted operating income as a % of total revenues2.5%0.9%5.8%3.4%
Premium revenues (by business):
Government28,10825,96884,38576,8002,1408.2%7,5859.9%
Commercial6,4617,77119,09523,931-1,310-16.9%-4,836-20.2%

Income Statement

The following table summarizes the Pharmacy & Consumer Wellness segment’s performance for the respective periods: (in millions)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025Nine Months Ended September 30, – 2025Change – Three Months Ended September 30, 2026 vs 2025 – $Change – Three Months Ended September 30, 2026 vs 2025 – %Change – Nine Months Ended September 30, 2026 vs 2025 – $Change – Nine Months Ended September 30, 2026 vs 2025 – %
Products34,80735,50399,29899,730-696-2.0%-432-0.4%
Services6917112,0051,977-20-2.8%281.4%
Total revenues35,49836,214101,303101,707-716-2.0%-404-0.4%
Cost of products sold28,70029,64781,77283,005-947-3.2%-1,233-1.5%
Gross profit (8)6,7986,56719,53118,7022313.5%8294.4%
Gross margin (Gross profit as a % of total revenues) (8)19.2%18.1%19.3%18.4%
Operating expenses5,2255,15315,41315,688721.4%-275-1.8%
Operating expenses as a % of total revenues14.7%14.2%15.2%15.4%
Operating income1,5731,4144,1183,01415911.2%1,10436.6%
Operating income as a % of total revenues4.4%3.9%4.1%3%
Adjusted operating income (1)1,6351,4784,3074,12915710.6%1784.3%
Adjusted operating income as a % of total revenues4.6%4.1%4.3%4.1%
Revenues (by major goods/service lines):
Pharmacy29,72530,42883,62984,135-703-2.3%-506-0.6%
Front Store5,1645,19215,83015,803-28-0.5%270.2%
Other6095941,8441,769152.5%754.2%
Prescriptions filled (5) (6)470461.41,378.21,3358.61.9%43.23.2%
Same store sales increase (decrease): (9)
Total-0.6%14.3%1.5%14.6%
Pharmacy-0.6%16.8%1.7%17.5%
Front Store-0.6%1.5%0.5%1.5%
Prescription volume (6)3.9%8.9%5.8%7.3%

Balance Sheet

September 30, 2026 — (Unaudited) (in millions)

September 30, 2026December 31, 2025
Cash and cash equivalents11,7388,453
Investments3,1492,145
Accounts receivable, net42,07339,779
Inventories18,24019,246
Other current assets4,1925,091
Total current assets79,39274,714
Long-term investments34,06632,669
Property and equipment, net13,32213,083
Operating lease right-of-use assets14,22614,973
Goodwill85,47885,478
Intangible assets, net24,22425,508
Other assets7,3677,113
Total assets258,075253,538
Liabilities:
Accounts payable17,87517,641
Pharmacy claims and discounts payable26,29626,344
Health care costs payable16,85815,399
Accrued expenses and other current liabilities25,78722,387
Other insurance liabilities9041,116
Current portion of operating lease liabilities1,9201,737
Current portion of long-term debt3,4574,068
Total current liabilities93,09788,692
Long-term operating lease liabilities12,69713,643
Long-term debt57,22360,502
Deferred income taxes3,8663,832

Cash Flow

Nine Months Ended September 30, — (Unaudited) (in millions)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net income (loss)8,123-1,195
Adjustments required to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization3,3733,459
Goodwill impairment5,725
Stock-based compensation610400
Loss on sale of subsidiary236
Gain on deconsolidation of subsidiary-483
Deferred income taxes and other items-344-440
Change in operating assets and liabilities3,556-453
Net cash provided by operating activities15,3187,249
Cash flows from investing activities:
Proceeds from sales and maturities of investments10,3829,640
Purchases of investments-13,592-11,045
Purchases of property and equipment-2,357-2,048
Acquisitions-15-429
Other379
Net cash used in investing activities-5,545-3,873
Cash flows from financing activities:
Commercial paper borrowings (repayments), net-872
Proceeds from issuance of long-term debt3,969
Repayments of long-term debt-4,057-3,609
Dividends paid-2,578-2,552
Proceeds from exercise of stock options339308
Payments for taxes related to net share settlement of equity awards-175-145
Other-66-7
Net cash used in financing activities-6,537-2,908
Net increase in cash, cash equivalents and restricted cash3,236468
Cash, cash equivalents and restricted cash at the beginning of the period8,7128,884
Cash, cash equivalents and restricted cash at the end of the period11,9489,352

Cautionary Statement Concerning Forward-looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation. Statements in this press release that are forward-looking include, but are not limited to, the full-year 2026 guidance information, Mr. Joyner’s quotation and the information included in the reconciliations and endnotes. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual results may differ materially from those contemplated by the forward-looking statements due to the risks and uncertainties described in our Securities and Exchange Commission (“SEC”) filings, including those set forth in the Risk Factors section and under the heading “Cautionary Statement Concerning Forward-Looking Statements” in our most recently filed Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2026, June 30, 2026 and September 30, 2026 and our Current Reports on Form 8-K.

You are cautioned not to place undue reliance on CVS Health’s forward-looking statements. CVS Health’s forward-looking statements are and will be based upon management’s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. CVS Health does not assume any duty to update or revise forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise.

Investor Contact: Larry McGrath | Executive Vice President, Capital Markets | (800) 201-0938

Media Contact: Ethan Slavin | Executive Director, Corporate Communications | (860) 273-6095

- Tables Follow -⁶

CVS HEALTH CORPORATION

Condensed Consolidated Statements of Operations

(Unaudited)⁷

CVS HEALTH CORPORATION

Condensed Consolidated Balance Sheets

(Unaudited)⁸

CVS HEALTH CORPORATION

Condensed Consolidated Statements of Cash Flows

(Unaudited)⁹

Non-GAAP Financial Information... (truncated)for, or superior to, financial measures determined or calculated in accordance with GAAP. The Company’s definitions of its non-GAAP financial measures may not be comparable to similarly titled measures reported by other companies.

Non-GAAP financial measures such as consolidated adjusted operating income, adjusted earnings per share (“EPS”) and adjusted income attributable to CVS Health exclude from the relevant GAAP metrics, as applicable: amortization of intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance.

For the periods covered in this press release, the following items are excluded from the non-GAAP financial measures described above, as applicable, because the Company believes they neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance:

• The Company’s acquisition activities have resulted in the recognition of intangible assets as required under the acquisition method of accounting which consist primarily of trademarks, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired. Definite-lived intangible assets are amortized over their estimated useful lives and are tested for impairment when events indicate that the carrying value may not be recoverable. The amortization of intangible assets is reflected in operating expenses within each segment. Although intangible assets contribute to the Company’s revenue generation, the amortization of intangible assets does not directly relate to the underwriting of the Company’s insurance products, the services performed for the Company’s customers or the sale of the Company’s products or services. Additionally, intangible asset amortization expense typically fluctuates based on the size and timing of the Company’s acquisition activity. Accordingly, the Company believes excluding the amortization of intangible assets enhances the Company’s and investors’ ability to compare the Company’s past financial performance with its current performance and to analyze underlying business performance and trends. Intangible asset amortization excluded from the related non-GAAP financial measure represents the entire amount recorded within the Company’s GAAP financial statements, and the revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. Intangible asset amortization is excluded from the related non-GAAP financial measure because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised.

• The Company’s net realized capital gains and losses arise from various types of transactions, primarily in the course of managing a portfolio of assets that support the payment of insurance liabilities. Net realized capital gains and losses are reflected in net investment income (loss) within each segment. These capital gains and losses are the result of investment decisions, market conditions and other economic developments that are unrelated to the performance of the Company’s business, and the amount and timing of these capital gains and losses do not directly relate to the underwriting of the Company’s insurance products, the services performed for the Company’s customers or the sale of the Company’s products or services. Accordingly, the Company believes excluding net realized capital gains and losses enhances the Company’s and investors’ ability to compare the Company’s past financial performance with its current performance and to analyze underlying business performance and trends.

• During the three and nine months ended September 30, 2026 and 2025, the acquisition-related integration costs relate to the acquisitions of Signify Health, Inc. and Oak Street Health, Inc. The acquisition-related integration costs are reflected in operating expenses within the Corporate/Other segment.¹⁰

• During the three and nine months ended September 30, 2026, the Omnicare guarantee relates to an estimated contingent guarantee liability recorded in connection with agreements to resolve certain litigation and Chapter 11 bankruptcy matters involving Omnicare. Following bankruptcy court approval of the agreements in August 2026 and the determination that the sale of Omnicare’s assets is probable of occurring in the fourth quarter of 2026, the Company recorded an estimated contingent guarantee liability in the third quarter of 2026. The Omnicare guarantee is reflected in operating expenses within the Corporate/Other Segment.

• During the three and nine months ended September 30, 2025, the goodwill impairment charge relates to the Health Care Delivery reporting unit within the Health Services segment.

• During the three and nine months ended September 30, 2025, the Health Care Delivery clinic closure charge primarily relates to the write down of long-lived assets in connection with the closure of certain Oak Street Health clinics in 2026, as well as associated severance and employee-related costs. The Health Care Delivery clinic closure charge was reflected in operating expenses within the Health Services segment.

• During the three and nine months ended September 30, 2025, the opioid litigation charge relates to a change in the Company’s accrual related to ongoing opioid litigation matters.

• During the nine months ended September 30, 2025, the Company recorded legacy litigation charges related to two court decisions associated with its past business practices. The legacy litigation charges were reflected in operating expenses within the Pharmacy & Consumer Wellness and Health Services segments.

• ... (truncated)untable Care assets represents the pre-tax loss on the divestiture of the Company’s Medicare Shared Savings Program (“MSSP”) operations, as well as costs incurred in connection with the wind down of the Company’s ACO REACH operations. The loss on Accountable Care assets was reflected in operating expenses within the Health Services segment.

• During the nine months ended September 30, 2025, the office real estate optimization charges primarily relate to the abandonment of leased real estate and the related right-of-use assets and property and equipment in connection with the Company’s evaluation of corporate office real estate space. The office real estate optimization charges were reflected in operating expenses within each segment.

• During the three and nine months ended September 30, 2025, the gain on deconsolidation of subsidiary relates to Omnicare, a wholly-owned indirect subsidiary of CVS Health Corporation, and certain of its subsidiary entities (collectively, the “Omnicare Entities”). In September 2025, the Omnicare Entities voluntarily initiated Chapter 11 proceedings under the U.S. Bankruptcy Code, at which time the Company determined that it no longer retained control of the Omnicare Entities and deconsolidated the subsidiaries.

• The corresponding tax benefit or expense related to the items excluded from adjusted income attributable to CVS Health and Adjusted EPS above. The nature of each non-GAAP adjustment is evaluated to determine whether a discrete adjustment should be made to the adjusted income tax provision.

See endnotes (1) and (2) on page²⁰ for definitions of non-GAAP financial measures. Reconciliations of each non-GAAP financial measure to the most directly comparable GAAP financial measure are presented on pages¹² through¹⁴ and page¹⁹.¹¹

Reconciliations of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures

Adjusted Operating Income

(Unaudited)

The following are reconciliations of consolidated operating income (loss) (GAAP measure) to consolidated adjusted operating income, as well as reconciliations of segment GAAP operating income (loss) to segment adjusted operating income (loss):¹²¹³

Adjusted Earnings Per Share

(Unaudited)

The following are reconciliations of net income (loss) attributable to CVS Health to adjusted income attributable to CVS Health and calculations of GAAP diluted earnings (loss) per share and Adjusted EPS:¹⁴

Supplemental Information

(Unaudited)

The following are reconciliations of financial measures of the Company’s segments to the consolidated totals:

_____________________________________________

(a)

Intersegment revenue eliminations relate to intersegment revenue generating activities that occur between the Health Care Benefits segment, the Health Services segment, and/or the Pharmacy & Consumer Wellness segment.¹⁵

Supplemental Information

(Unaudited)

Health Care Benefits segment

The following table summarizes the Health Care Benefits segment’s performance for the respective periods:

The following table summarizes the Health Care Benefits segment’s medical membership for the respective periods:

The following table summarizes the Health Care Benefits segment’s days claims payable for the respective periods:¹⁶

Supplemental Information

(Unaudited)

Health Services segment

The following table summarizes the Health Services segment’s performance for the respective periods:¹⁷

Supplemental Information

(Unaudited)

Pharmacy & Consumer Wellness segment

The following table summarizes the Pharmacy & Consumer Wellness segment’s performance for the respective periods:¹⁸

Adjusted Earnings Per Share Guidance

(Unaudited)

The following reconciliations of projected net income attributable to CVS Health to projected adjusted income attributable to CVS Health and calculations of projected GAAP diluted EPS and projected Adjusted EPS contain forward-looking information. All forward-looking information involves risks and uncertainties. Actual results may differ materially from those contemplated by the forward-looking information for a number of reasons as described in our SEC filings, including those set forth in the Risk Factors section and under the heading “Cautionary Statement Concerning Forward-Looking Statements” in our most recently filed Annual Report on Form 10-K and our most recently filed Quarterly Report on Form 10-Q. See “Non-GAAP Financial Information” earlier in this press release and endnote (2) later in this press release for more information on how we calculate Adjusted EPS.¹⁹

Endnotes

(1)

The Company defines adjusted operating income as operating income (loss) (GAAP measure) excluding the impact of amortization of intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance, such as acquisition-related integration costs, the Omnicare guarantee, goodwill impairment charges, Health Care Delivery clinic closure charges, opioid litigation charges, certain legacy litigation charges, losses on Accountable Care assets and office real estate optimization charges. The chief operating decision maker (the “CODM”) uses adjusted operating income as its principal measure of segment performance as it enhances the CODM’s ability to compare past financial performance with current performance and analyze underlying business performance and trends. The consolidated measure is not determined in accordance with GAAP and should not be considered a substitute for, or superior to, the most directly comparable GAAP measure, consolidated operating income (loss). See “Non-GAAP Financial Information” earlier in this press release for additional information regarding the items excluded from consolidated operating income (loss) in determining consolidated adjusted operating income.

(2)... (truncated)alculated by dividing net income (loss) attributable to CVS Health and adjusted income attributable to CVS Health by the Company’s weighted average diluted shares outstanding. The Company defines adjusted income attributable to CVS Health as net income (loss) attributable to CVS Health (GAAP measure) excluding the impact of amortization of intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance, such as acquisition-related integration costs, the Omnicare guarantee, goodwill impairment charges, Health Care Delivery clinic closure charges, opioid litigation charges, certain legacy litigation charges, losses on Accountable Care assets, office real estate optimization charges, the gain on deconsolidation of subsidiary, as well as the corresponding income tax benefit or expense related to the items excluded from adjusted income attributable to CVS Health. Adjusted EPS for the three and nine months ended September 30, 2025 is calculated utilizing weighted average diluted shares outstanding, which include potential common shares in each period, as the impact of the potential common shares was dilutive. The potential common shares were excluded from the calculations of GAAP loss per share for the three and nine months ended September 30, 2025, as the shares would have had an anti-dilutive effect as a result of the GAAP net loss in each period. See “Non-GAAP Financial Information” earlier in this press release for additional information regarding the items excluded from net income (loss) attributable to CVS Health in determining adjusted income attributable to CVS Health.

(3)

Medical benefit ratio is calculated by dividing the Health Care Benefits segment’s health care costs by premium revenues and represents the percentage of premium revenues spent on medical benefits for the segment’s insured members. Management uses MBR to assess the underlying business performance and underwriting of its insurance products, understand variances between actual results and expected results and identify trends in period-over-period results. MBR provides management and investors with information useful in assessing the operating results of the Health Care Benefits segment’s insured products.

(4)

Medical membership represents the number of members covered by the Health Care Benefits segment’s insured and ASC medical products and related services at a specified point in time. Management uses this metric to understand variances between actual medical membership and expected amounts as well as trends in period-over-period results. This metric provides management and investors with information useful in understanding the impact of medical membership on the Health Care Benefits segment’s total revenues and operating results.

(5)

Pharmacy claims processed represents the number of prescription claims processed through the Company’s pharmacy benefits manager and dispensed by either its retail network pharmacies or the Company’s mail and specialty pharmacies. Prescriptions filled represents the number of prescriptions dispensed through the Pharmacy & Consumer Wellness segment’s retail pharmacies and infusion services operations, as well as through the Omnicare long-term care pharmacies prior to their deconsolidation in September 2025. Management uses these metrics to understand variances between actual claims processed and prescriptions dispensed, respectively, and expected amounts as well as trends in period-over-period results. These metrics provide management and investors with²⁰ information useful in understanding the impact of pharmacy claim volume and prescription volume, respectively, on segment total revenues and operating results.

(6)

Includes an adjustment to convert 90-day prescriptions to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription.

(7)

Days claims payable is calculated by dividing the Health Care Benefits segment’s health care costs payable at the end of each quarter by its average health care costs per day during such quarter. Management and investors use this metric as one of the indicators of the adequacy of the health care costs payable liability at the end of each quarter.

(8)

Gross profit is calculated as the segment’s total revenues less its cost of products sold, and, for the Health Services segment, health care costs. Gross margin is calculated by dividing the segment’s gross profit by its total revenues and represents the percentage of total revenues that remains after incurring direct costs associated with the segment’s products sold and services provided. Gross margin provides investors with information that may be useful in assessing the operating results of the Company’s Health Services and Pharmacy & Consumer Wellness segments.

(9)... (truncated)stores.²¹

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · CVS HEALTH earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.